Fig. 1From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma a Overall survival after treatment with HD IL-2 therapy in patients treated with prior Ipilimumab as compared to those patients not treated with prior ICB. b Overall survival from the time of diagnosis with metastatic melanoma in patients treated with ipilimumab prior to HD IL-2 as compared to those patients not treated with prior ICBBack to article page